INTRODUCTION {#s1}
============

Breast cancer is one of the most frequent malignancies worldwide and represents an important public health problem \[[@R1], [@R2]\]. Evaluating the status of axillary lymph nodes (ALNs) is essential in deciding appropriate treatment and staging as well as predicting the long-term survival in breast cancer \[[@R3]\]. Although significant progress has been made in the genetic and molecular characterization of breast malignant lesions, axillary lymph node involvement is the single most important prognostic variable \[[@R4]--[@R7]\].

Previous studies have used various factors to predict lymph node metastasis \[[@R8]--[@R11]\] such as magnetic resonance spectroscopy, DNA microarray assay for gene expression in breast cancer tissues, and P53 and Ki67 in patients with estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer \[[@R9], [@R12], [@R13]\].

The spread of screening mammography has led to increasing occurrences of microcalcifications \[[@R14], [@R15]\]. Mammographically detected microcalcifications represent the earliest mammographic findings of non-palpable breast cancers, which are found in approximately 70% of minimal breast carcinomas \[[@R16], [@R17]\] To the best of our knowledge, no studies have determined whether a calcification features combined with clinicopathological parameters would enable superior prediction of LN metastasis in IDC of breast. Therefore, we investigated whether the clinicopathological parameters and imaging features of the patterns of mammographically detected calcifications differed between LN (+) tumors and LN (−) tumors.

RESULTS {#s2}
=======

Hierarchical clustering displayed clear grouping of samples of LN involvement (Figure [1](#F1){ref-type="fig"}).
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For microcalcification-associated breast cancers, seven selected features (age, tumor size, Ki-67 status, lymphovascular invasion, calcification range, calcification diameter and calcification density) were significantly associated with LN status (all *P* \< 0.05). Multivariate logistic regression analysis showed that three risk factors (age: older vs. younger OR: 0.973 *P* = 0.006, tumor size: larger vs. smaller OR: 1.671, *P* \< 0.001 and calcification density: calcifications \> 20/cm^2^ vs. calcifications ≤ 20/cm^2^ OR: 1.698, *P* \< 0.001) were significant independent predictors. This model had an area under the receiver operating characteristic curve (AUC) of 0.701. The nodal staging (N0 and N1 χ^2^ = 5.701, *P* = 0.017; N0 and N2 χ^2^ = 6.614, *P* = 0.013) was significantly positively associated with calcification density (Figure [2](#F2){ref-type="fig"}).
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We demonstrated that larger tumor size, younger age and calcifications \> 20/cm^2^ in density (Figure [3](#F3){ref-type="fig"}) were associated with a significantly higher incidence of LN metastasis (Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}). This model had an AUC of 0.701.
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###### Clinical and pathologic characteristics of 419 patients between LN(−) and LN(+) tumors

  Characteristics                        LN (−)          LN (+)          *P* value
  -------------------------------------- --------------- --------------- ------------
  Age, years, mean (range) (*N* = 418)   52.65 ± 10.82   50.31 ± 11.19   **0.031**
  Tumor size (cm) (*N* = 405)            1.87 ± 1.04     2.48 ± 1.23     **0.000**
  ER (*N* = 419)                         52.03 ± 39.62   50.77 ± 38.96   0.745
  PR (*N* = 419)                         30.93 ± 36.28   31.27 ± 35.63   0.922
  Ki-67 (*N* = 413)                      25.49 ± 19.56   29.63 ± 21.36   **0.041**
  ER (*N* = 419)                                                         **0..844**
   Negative                              77 (34.1)       64 (33.2)       
   Positive                              149 (65.9)      129 (66.8)      
  PR (*N* = 419)                                                         **0.403**
   Negative                              117 (51.8)      92 (47.7)       
   Positive                              109 (48.2)      101 (52.3)      
  Ki-67 (*N* = 413)                                                      0.016
   Negative                              77 (34.5)       45 (23.7)       
   Positive                              146 (65.5)      145 (76.3)      
  HER-2 (*N* = 346)                                                      0.926
   Negative                              105 (55.6)      88 (56.1)       
   Positive                              84 (44.4)       69 (43.9)       
  Histological grade (*N* = 418)                                         **0.130**
   I                                     19 (8.4)        9 (4.7)         
   II--III                               207 (91.6)      183 (95.3)      
  Lymphovascular invasion (*N* = 413)                                    0.000
   Yes                                   31 (13.9)       86 (45.3)       
   No                                    192 (86.1)      104 (54.7)      

###### Comparison of features A-E between LN(−) and LN(+) tumors (*N* = 419)

                                               LN (−)(*n* = 226)   LN (+)(*n* = 226)   *P* value
  -------------------------------------------- ------------------- ------------------- -----------
  **Feature A (Calcification morphology)**                                             0.123
   Fine linear/branching/pleomorphic           55 (24.3)           60 (31.1)           
   Amorphour/Coarse heterogenous               171 (75.7)          133 (68.9)          
  **Feature B (Calcification distrubution)**                                           0.058
   Grouped or Clustered or Regional            169 (74.8)          128 (66.3)          
   Linear or Segmental                         57 (25.2)           65 (33.7)           
  **Feature C**                                                                        **0.019**
   Calcifications ≤ 2 cm in range              170 (75.2)          125 (64.8)          
   Calcifications \> 2 cm in range             56 (24.8)           68 (35.2)           
  **Feature D**                                                                        **0.047**
   Calcifications ≤ 0.5 mm in diameter         172 (76.1)          130 (67.4)          
   Calcifications \> 0.5 mm in diameter        54 (23.9)           63 (32.6)           
  **Feature E**                                                                        **0.005**
   Calcifications ≤ 20/cm^2^ in density        169 (74.8)          120 (62.2)          
   Calcifications \> 20/ cm^2^ in density      57 (25.2)           73 (37.8)           

Note -- Numbers in parentheses are percentages.

###### Binary logistic regression analysis of prognostic factors for lymph node metastasis of breast cancer

               β        S.E.    Wald     Sig.    OR      95.0% C.I.for EXP (β)   
  ------------ -------- ------- -------- ------- ------- ----------------------- -------
  Age          −0.028   0.01    7.62     0.006   0.973   0.954                   0.992
  Tumor size   0.514    0.107   23.068   0.000   1.671   1.355                   2.061
  Feature E    0.529    0.231   5.264    0.022   1.698   1.080                   2.668
  Constant     0.017    0.550   0.001    0.975   1.017                           

Nodal staging (N0 and N1 χ^2^ = 5.701, *P* = 0.017; N0 and N2 χ^2^ = 6.614, *P* = 0.013) was significantly associated with Feature E (Tables [4](#T4){ref-type="table"}, [5](#T5){ref-type="table"}).

###### Comparison of features A-E between different nodal staging (TNM stage *N* = 419)

                                               N0(*n* = 226)   N1(*n* = 114)   N2(*n* = 49)   N3(*n* = 30)   *P* value
  -------------------------------------------- --------------- --------------- -------------- -------------- -----------
  **Feature E**                                                                                              **0.027**
   *Calcifications ≤ 20/cm^2^ in density*      169 (58.5)      71 (24.6)       28 (9.7)       21 (7.3)       
   *Calcifications* \> *20/cm^2^ in density*   57 (43.8)       43 (33.1)       21 (16.2)      9 (6.9)        

Note -- Numbers in parentheses are percentages.

###### Comparison of feature E between different nodal staging

               χ^2^        *P* value
  ---- ------- ----------- -----------
  N0   N1      5.701       **0.017**
  N2   6.164   **0.013**   
  N3   0.316   0.574       
  N1   N2      0.379       0.538
  N3   0.613   0.434       
  N2   N3      1.306       0.253

Regarding the microcalcification-associated breast cancers, 68 (17.5%) were Luminal A, 197 (50.6%) were Luminal B, 94 (24.2%) were HER2 and 30 (7.7%) were basal subtypes (*N* = 389). We demonstrated that the Luminal B subtype (Luminal B vs. Luminal A, Luminal B vs. others, Luminal B vs. Basal) have the highest risk of LN metastasis (Table [1](#T1){ref-type="table"}). Univariate analysis found that three features (tumor size, lymphovascular invasion and calcification range) were significantly associated with LN status of the Luminal B molecular subtype (all *P* \< 0.05). Multivariate analysis showed that calcification \> 2 cm in range (OR: 1.878 95%CI: 1.150 to 3.067) and tumor size (OR: 1.882 95%CI: 1.327 to 2.670) were independently predictive of LN metastasis of the Luminal B molecular subtype (Table [6](#T6){ref-type="table"}). This model had an AUC of 0.667.

###### Breast cancer molecular subtypes between LN(−) and LN(+) tumors

  Characteristics                       LN (−)       LN (+)       *P* value
  ------------------------------------- ------------ ------------ -----------
  Molecular subtypes (*N* = 389)                                  **0.013**
   Luminal A                            46 (21.8)    22 (12.4)    
   Luminal B                            93 (44.1)    104 (58.4)   
   HER2                                 52 (24.6)    42 (23.6)    
   Basal                                20 (9.5)     10 (5.6)     
  Luminal A vs. others (*N* = 389)                                **0.015**
   Yes                                  46 (21.8)    22 (12.4)    
   No                                   165 (78.2)   156 (87.6)   
  Luminal B vs. others (*N* = 389)                                **0.005**
   Yes                                  93 (44.1)    104 (58.4)   
   No                                   118 (55.9)   74 (41.6)    
  HER2 vs. others (*N* = 389)                                     0.810
   Yes                                  52 (24.6)    42 (23.6)    
   No                                   159 (75.4)   136 (76.4)   
  Basal vs. others (*N* = 389)                                    0.155
   Yes                                  20 (9.5)     10 (5.6)     
   No                                   191 (90.5)   168 (94.4)   
  Luminal A vs. Luminal B (*N* = 265)                             **0.004**
   Luminal A                            46 (33.1)    22 (17.5)    
   Luminal B                            93 (66.9)    104 (82.5)   
  Luminal A vs. HER2 (*N* = 162)                                  0.113
   Luminal A                            46 (46.9)    22 (34.4)    
   HER2                                 52 (53.1)    42 (65.6)    
  Luminal A vs. Basal (*N* = 98)                                  0.924
   Luminal A                            46 (69.7)    22 (68.8)    
   Basal                                20 (30.3)    10 (31.3)    
  Luminal B vs. HER2 (*N* = 291)                                  0.196
   Luminal B                            93 (64.1)    104 (71.2)   
   HER2                                 52 (35.9)    42 (28.8)    
  Luminal B vs. Basal (*N* = 227)                                 0.047
   Luminal B                            93 (82.3)    104 (91.2)   
   Basal                                20 (17.7)    10 (8.8)     
  HER2 vs. Basal (*N* = 124)                                      0.273
   HER2                                 52 (72.2)    42 (80.8)    
   Basal                                20 (27.8)    10 (19.2)    

There were no significant differences in clinicopathological parameters or BI-RADS 3--5 microcalcifications between the LN (−) and LN (+) invasive ductal carcinoma (Luminal A, HER2, Basal molecular subtype).

DISCUSSION {#s3}
==========

Mammographically detected calcifications are frequently used as the only sign of breast cancer \[[@R18]\]. Mammography is the gold standard modality for detecting microcalcifications \[[@R19]\]. BI-RADS 3--5 microcalcifications are a characteristic appearance of breast cancer at mammographic imaging and a well-known criterion in the diagnosis of the disease. LN metastasis is one of the most important prognostic factors in IDC patients. Patients with LN metastasis have an approximately four- to eight-fold higher mortality rate than those without nodal involvement \[[@R20]\]. To the best of our knowledge, no studies have determined whether calcification features combined with clinicopathological parameters would enable the prediction of LN metastasis.

Microcalcifications depicted on mammographic imaging develop in (i) luminal secretions or (ii) the necrotic cellular debris in the lumen of the distended ducts \[[@R21]\]. The microcalcifications that develop in necrotic cellular debris are irregular borders as well as linear with clefts in a focal, segmental or regional distribution \[[@R21]\]. However, the microcalcifications that develop in luminal secretions are round and punctate as well as amorphous calcifications within a cluster \[[@R21]\]. The characteristics of breast microcalcifications continue to attract interest. Hashimoto and coworkers found that patients with microcalcifications were significantly more likely to have LN metastases \[[@R19]\]. Li and coworkers found that malignant-appearing microcalcifications were significantly associated with a LN (+) status and that they always presented in breast cancer patients who were non-menopausal as well as with a family history of carcinoma \[[@R22]\]. Howland and coworkers reported that HER2 positivity is recognized to be associated with a higher incidence of LN metastases \[[@R23]\]. Several factors, including a higher ER-positivity rate, the prevalence of c-myc expression \[[@R24]\], as well as the elevated expression of osteopontin \[[@R25]\] and the ryanodine receptor 3 gene \[[@R26]\], were believed to contribute to the microcalcifications. Several factors, including HER2 positivity \[[@R23]\], the number of a CK19 mRNA copies \[[@R27]\], an elevated expression of osteopontin \[[@R25]\], T size and LVI \[[@R27]\], tumor grade \[[@R28]\], and clinical stage \[[@R28]\] were believed to contribute to lymph node metastases. However, questions regarding the most significant factor affecting lymph node metastases or the presence of microcalcifications remain unanswered.

If it is possible to predict the LN metastasis based on the patterns of mammographically detected calcifications, this information will be essential for clinical decision-making \[[@R29]\]. The multivariate analysis in our study demonstrates that the clinicopathological and imaging parameters of infiltrating ductal carcinoma, which consisted of three selected features (age, tumor size and Feature E), were statistically significant independent predictors. We demonstrated that larger tumor size, younger age and calcifications \> 20/ cm^2^ were associated with a significantly higher rate of LN metastasis. However, other studies did not perform other measurements such as calcification range, calcification diameter and calcification density to more comprehensively evaluate the appearance of these calcifications. Additionally, our study is the first study to identify the risk factors in IDC, including a relatively large number of breast cancer patients. The discrimination of the model for predicting LNM was 0.70 in this study was 0.70 (95%, C.I. 0.69--0.73), thereby confirming a high level of reliability.

A previous study reported that HER2 positivity is associated with a higher rate of LN metastases \[[@R23]\]; this was not confirmed by our study. However, little is known about the incidence of microcalcification-associated breast cancers \[[@R15]\]. Our study found that Luminal B tumors (Luminal B vs. others, Luminal B vs. Luminal A, Luminal B vs. basal) have the highest risk of LN metastasis. Future data from large studies will be of interest. Our multivariate analysis showed that calcification \> 2 cm in range (OR: 1.878 95% CI: 1.150 to 3.067) and tumor size (OR: 1.882 95% CI: 1.327 to 2.670) were independently predictive of LN metastasis of the Luminal B molecular subtype. The discrimination of the present study\'s model for predicting LNM was 0.67. And future data from large studies will be of interest.

Our study had limitations. First, we did not evaluate interobserver variability because this was a retrospective analysis and two radiologists reviewed the mammographic images in consensus. Secondly, we did not determine whether microcalcifications were combined with associated findings such as focal asymmetry, architectural distortion, or suspicious masses. Further study is needed to explore additional relationships. Thirdly, micrometastases were found in 22 (5.3%) of 419 patients. Due to the limitations of our raw data (micrometastases 5.3%), the clinicopathological parameters and BI-RADS 3--5 microcalcifications only predict positive lymph node status.

In conclusion, our findings clearly show that age, tumor size and Feature E (≤ 20 or \> 20/cm^2^ in density) can be conveniently used to facilitate the preoperative individualized prediction of lymph node metastasis in patients with IDC. The discriminatory power for this prediction model was good with an overall AUC of 0.70. This information may be useful for clinical decision-making in breast cancer patients.

MATERIALS AND METHODS {#s4}
=====================

Study subjects {#s4_1}
--------------

The ethics committee approved the study (Guangdong Provincial Traditional Chinese Medicine Hospital), and written informed consent was obtained from all breast cancer patients. Patients were included in this analysis if information on (1) invasive ductal carcinoma of breast (2) Breast Imaging Reporting and Data System (BI-RADS) 3--5 microcalcifications and (3) histopathologic information were available.

Between January 2011 and April 2016, 419 female patients (aged 51.7 ± 10.8 years; range, 25--88 years) met the selection criteria and were included.

Mammography interpretations {#s4_2}
---------------------------

The digital mammograms acquired were analyzed using a standard four-view film. All cases of microcalcifications were classified according to the method proposed by the American College of Radiology, and only those classified as BI-RADS 3--5 were selected \[[@R16], [@R30], [@R31]\]. All of the parameters of the calcifications (Features A-E) were divided in a binary manner. We conducted a detailed image analysis to evaluate morphology (Feature A (1) Fine linear or branching or pleomorphic (2) amorphous or coarse heterogeneous), distribution (Feature B (1) grouped or clustered or regional (2) linear or segmental), range (Feature C (1) calcifications measuring ≤ 2 cm or (2) \> 2 cm in range), diameter (Feature D (1) ≤ 0.5 mm or (2) \> 0.5 mm in diameter) and density (Feature E (1) ≤ 20 or (2) \> 20/cm^2^ in density).

Histopathologic assessment {#s4_3}
--------------------------

Histopathologic information, including the progesterone receptor status, histological grade, ER status, HER-2, Ki-67 (Ki67 ≤ 14% was defined as low expression and Ki67 \> 14% as high expression \[[@R32]--[@R34]\]), tumor size, lymphovascular invasion (IVI) and LN status (number of ALND, ALND(+), number of SLNB, SLNB(+) and micrometastasis), were obtained from the pathology reports.

Tumors were divided into 4 molecular subtypes according to previous reports \[[@R32]--[@R34]\]: (1) the Luminal A subtype, (2) the Luminal B subtype, (3) the HER-2 enriched subtype, and (4) the Basal subtype.

HER2-positive status (IHC 3+ or Fish+ and IHC 0/1+ or Fish-) was defined by the 2013 American Society of Clinical Oncology/College of American Pathology guidelines in our study \[[@R25], [@R35]\].

LN was considered positive based on the HE staining and IHC test. Each node was classified as having (i) macrometastasis (\>2.0 mm in size), (ii) micrometastasis (\> 0.2--2.0 mm in size), (iii) isolated tumor cells (ITC \< 0.2 mm in size), or (iv) no detectable tumor cells (the Seventh Edition of the American Joint Committee on Cancer Classification) \[[@R24]\]. LN (+) status was defined as having micrometastatic or metastatic LN tumors; LN (−) status was defined as LNs with ITC or no detectable tumor cells \[[@R36]\] (Figure [4](#F4){ref-type="fig"}).

![LN-positive and LN-negative status](oncotarget-08-30190-g004){#F4}

Statistical analysis {#s4_4}
--------------------

Associations between the clinicopathological parameters and the patterns of mammographically detected calcifications as well as LN status were evaluated. A univariate analysis of variables was carried out using a Chi-square test and one-way analysis of variance (ANOVA) with a *P value* of \< 0.05 as the limit of statistical significance. The variables that obtained a *P value* \< 0.1 with univariate analysis were subjected to multistep multivariate binary logistic regression (version 15.0; SPSS Company, Chicago, IL).
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